Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-5269Fax+1 617-632-3479- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
- Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
- Harvard Medical SchoolClass of 2002
Certifications & Licensure
- FL State Medical License 2022 - Present
- MA State Medical License 2004 - 2025
- VT State Medical License 2023 - 2024
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
- A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2011 Apr 01
- A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.Xiong, N., Sawyer, H., Polak, M., Needham, H., Geddes, M., Koppermann, L., Shea, M., Castro, C., Cheng, S., Konstantinopoulos, P., Krasner, C., Liu, J., Matulonis, U.,...> ;Gynecologic Oncology Reports. 2024 Apr 1
- Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.Corcoran, R., Do, K., Kim, J., Cleary, J., Parikh, A., Yeku, O., Xiong, N., Weekes, C., Veneris, J., Ahronian, L., Mauri, G., Tian, J., Norden, B., Michel, A., Van Sev...> ;Clinical Cancer Research. 2024 Mar 8
- Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.St Laurent, J., Liu, J., Quade, B., Davis, M., Abel, M.> ;Gynecologic Oncology Reports. 2024 Feb 1
- Join now to see all
Press Mentions
- Nivolumab/bevacizumab Combo Promising in Relapsed Ovarian CancerOctober 19th, 2019
- OncLive® Presents Latest State of the Science Summit™ on Ovarian Cancer and STSNovember 29th, 2018
- Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian CancerJune 9th, 2017
- Join now to see all
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Boston Children's HospitalBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
- Salem HospitalSalem, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: